Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11040924 | 0.98 | GGPS1 (0.38) | FDPSGGPS1SMPD1CES2LPAR1 | |
| SCHEMBL9123282 | 0.98 | GGPS1 (0.38) | FDPSGGPS1SMPD1CES2LPAR1 | |
| SCHEMBL9800901 | 0.98 | GGPS1 (0.38) | FDPSGGPS1SMPD1CES2LPAR1 | |
| SCHEMBL11280542 | 0.98 | GGPS1 (0.38) | FDPSGGPS1SMPD1CES2LPAR1 | |
| SCHEMBL8819694 | 0.98 | GGPS1 (0.38) | FDPSGGPS1SMPD1CES2LPAR1 | |
| SCHEMBL11043523 | 0.93 | FDPS (0.31) | FDPS | |
| SCHEMBL192803 | 0.91 | — | — | |
| SCHEMBL9322915 | 0.88 | FFAR1 (0.31) | — | |
| SCHEMBL10840235 | 0.88 | FFAR1 (0.31) | — | |
| SCHEMBL8763158 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | disclosed |
| EP-0025907-B1 | HALOGENATED TERTIARY ALKYL ISOCYANATES AND PROCESS FOR THEIR PREPARATION | BASF Aktiengesellschaft (DE) | 1984-06-20 | — | — | EP | disclosed |
| US-4344891-A | Halogenated tertiary alkyl isocyanates and their preparation | BASF AKTIENGESELLSCHAFT (DE) | 1982-08-17 | — | — | US | disclosed |
| EP-0025907-A1 | Halogenated tertiary alkyl isocyanates and process for their preparation | BASF Aktiengesellschaft (DE) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | TLR1, TPMT, NOD1 | FDPS 290/4885GGPS1 188/4885SMPD1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.